In vitro activity of biapenem against clinical isolates of gram-positive and gram-negative bacteria
Open Access
- 1 September 1993
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 37 (9) , 2009-2016
- https://doi.org/10.1128/aac.37.9.2009
Abstract
The in vitro activity of biapenem, a new carbapenem previously designated L-627, was compared with those of imipenem and several other antimicrobial agents against 771 clinical bacterial isolates. Against gram-positive organisms, biapenem was found to be approximately as active as imipenem, inhibiting 90% of isolates of most species at concentrations within one dilution of the MIC of imipenem for 90% of the isolates. Against gram-negative organisms and Bacteroides fragilis, biapenem was at least as active as and often more active than imipenem, with MICs for 90% of the isolates two- to eightfold lower than those of imipenem.Keywords
This publication has 7 references indexed in Scilit:
- In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteriaAntimicrobial Agents and Chemotherapy, 1993
- In vitro activity of L-627, a new carbapenemAntimicrobial Agents and Chemotherapy, 1992
- In vitro and in vivo activities of LJC10,627, a new carbapenem with stability to dehydropeptidase IAntimicrobial Agents and Chemotherapy, 1991
- In vitro activity of LJC10,627, a new carbapenem antibiotic with high stability to dehydropeptidase IAntimicrobial Agents and Chemotherapy, 1990
- Purification and characterization of inducible beta-lactamases in Aeromonas sppAntimicrobial Agents and Chemotherapy, 1990
- Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830)Diagnostic Microbiology and Infectious Disease, 1989
- In-vitro and in-vivo antibacterial activity of imipenem against clinical isolates of bacteriaJournal of Antimicrobial Chemotherapy, 1983